Oppenheimer raised the firm’s price target on enGene (ENGN) to $33 from $30 and keeps an Outperform rating on the shares. The firm believes the reveal from the pivotal LEGEND trial in high-risk NMIBC is not only impressive in its own right – highlighted by detalimogene’s 62% 6-month complete response rate – but also addresses the market’s skepticism following last September’s initial showing, which preceded changes that brought the trial’s design closer to current standards for this indication.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- enGene price target raised to $10 from $4 at UBS
- Cautious Hold Rating for enGene Holdings Amid Competitive Trial Results and Market Uncertainty
- enGene price target raised to $21 from $18 at Citizens JMP
- Here’s Why enGene Holdings Stock Is Soaring Today
- Midday Fly By: SoftBank exits Nvidia, CoreWeave cuts guidance